Company / Operating Income
Syndax Pharmaceuticals Inc Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$273.1M
FY2025
5-year range
-$339.7M / -$57.5M
FY2021-FY2025
Trend
+19.6%
vs FY2024
Sector context
#161 of 204
Health Care
What the data says
Syndax Pharmaceuticals Inc's operating income of -$273M is lower than 79% of companies in the Health Care sector (FY2025). Operating Income returned to growth in FY2025 after 3 years of decline, reaching -$273M.
Based on SEC 10-K filings.
-$273M in FY2025.
Declined from -$230M to -$273M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 21% in Health CareTop 79% of 204This company -$273.1M Sector average $107.7M
▼
-353.5% below sector average
Key checks
Key Insights
- In FY2025, operating income increased 19.6% year-over-year.
- Ranks #161 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2017.
- Lowest operating income in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.08 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$273.1M | +19.6% |
| FY2024 | -$339.7M | -47.7% |
| FY2023 | -$230.0M | -51.5% |
| FY2022 | -$151.8M | -163.7% |
| FY2021 | -$57.5M | +24.2% |
| FY2020 | -$75.9M | -22.5% |
| FY2019 | -$62.0M | -41.6% |
| FY2018 | -$43.8M | -113.4% |
| FY2017 | -$20.5M | +3.8% |
| FY2016 | -$21.3M | -4.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026